Search results
Results from the WOW.Com Content Network
Augmentin 250, for example, contains 250 mg of amoxicillin and 125 mg of clavulanic acid. [ 12 ] [ 27 ] An intravenous preparation has been available in the UK since 1985, [ 28 ] but no parenteral preparation is available in the US; [ citation needed ] the nearest equivalent is ampicillin/sulbactam .
Clavulanic acid is a β-lactam drug that functions as a mechanism-based β-lactamase inhibitor.While not effective by itself as an antibiotic, when combined with penicillin-group antibiotics, it can overcome antibiotic resistance in bacteria that secrete β-lactamase, which otherwise inactivates most penicillins.
Amoxicillin is an antibiotic medication belonging to the aminopenicillin class of the penicillin family. The drug is used to treat bacterial infections [9] such as middle ear infection, strep throat, pneumonia, skin infections, odontogenic infections, and urinary tract infections. [9]
6-APA ((+)-6-aminopenicillanic acid) is a chemical compound used as an intermediate in the synthesis of β–lactam antibiotics. The major commercial source of 6-APA is still natural penicillin G. The semi-synthetic penicillins derived from 6-APA are also referred to as penicillins and are considered part of the penicillin family of antibiotics ...
The 6-aminopenicillanic acid nucleus consists of a thiazolidine ring attached to a β-lactam ring, which is the active moiety responsible for the antibacterial activity of the penicillin family. The substituent present on oxacillin is thought to impart resistance to degradation via bacterial β-lactamases.
Typically, this drug is not given through a rapid injection because the solution has high osmolality, which means it has a high concentration of particles; still, in emergency situations, it is possible to administer the drug through a rapid injection into a vein: despite the high osmolality, studies have shown that this method of ...
Ampicillin/sulbactam has a wide array of medical use for many different types of infectious disease. It is usually reserved as a second-line therapy in cases where bacteria have become beta-lactamase resistant, rendering traditional penicillin-derived antibiotics ineffective.
Azithromycin therapy in cystic fibrosis patients yields a modest respiratory function improvement, reduces exacerbation risk, and extends time to exacerbation up to six months; still, long-term efficacy data is a subject of ongoing research.